Shares of Q32 Bio QTTB lost nearly 77% yesterday after it reported mixed results from two separate phase IIa studies ...

Q32 Bio still sees potential for its anti-IL-7R antibody as an alopecia treatment despite failing a phase 2 eczema study—but ...

Q32 Bio Inc (QTTB) stock saw a decline, ending the day at $5.95 which represents a decrease of $-18.46 or -75.62% from the prior close of $24.41. The stock opened at $8 and touched a low of $5.8 ...

Q32 Bio delivered a "messy" update for its eczema and alopecia treatment, leading the biotech stock to collapse to a record ...

Oppenheimer lowered the firm’s price target on Q32 Bio (QTTB) to $20 from $80 and keeps an Outperform rating on the shares.

As previously reported, Guggenheim downgraded Q32 Bio (QTTB) to Neutral from Buy and removed the firm’s prior price target following the ...

BMO Capital lowered the firm’s price target on Q32 Bio (QTTB) to $22 from $64 but keeps an Outperform rating on the shares. The company ...

Shares of Q32 Bio (QTTB) plummeted over 60% in premarket trading Wednesday following mixed results from Phase 2a trials of ...

Analysts slashed their price targets for the Massachusetts biotech after ‘messy’ trial results in alopecia and eczema.

Q32 Bio reports Phase 2a SIGNAL-AA trial results for bempikibart in alopecia areata, showing safety and modest efficacy.

Shares of Q32 Bio were touching all-time lows in the after-hours market following results from a pair of Phase 2a clinical trials of the company's alopecia treatment bempikibart.

Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune homeostasis, today announced topline results from the ...